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Summary 
Background In models of dopaminergic neuronal loss, the dopamine agonist pramipexole has exhibited neuroprotective 
properties. The Pramipexole On Underlying Disease (PROUD) study was designed to identify whether early versus 
delayed pramipexole initiation has clinical and neuroimaging beneﬁ ts in patients with Parkinson’s disease (PD).
Methods Between May 24, 2006, and April 22, 2009, at 98 centres, we recruited patients with PD diagnosed within 
2 years and aged 30–79 years. We randomly assigned eligible patients (ratio 1:1), by a centralised, computerised 
randomisation schedule, to receive double-blind either placebo or pramipexole (1·5 mg a day) and followed them up 
for 15 months. At 9 months, or as early as 6 months if considered necessary, placebo recipients were assigned to 
pramipexole. In a neuroimaging substudy, striatal dopamine-transporter binding was assessed by SPECT. All patients, 
investigators, and independent raters were masked to study treatment. The primary endpoint was the 15-month 
change from baseline in total score on the uniﬁ ed Parkinson’s disease rating scale (UPDRS). This trial is registered 
with ClinicalTrials.gov, number NCT00321854.
Findings Of 535 patients, 261 were randomly assigned to receive pramipexole and 274 to receive placebo. At 15 months 
(n=411), adjusted mean change in UPDRS total score showed no signiﬁ cant diﬀ erence between early and delayed 
pramipexole (–0·4 points, 95% CI –2·2 to 1·4, p=0·65). 62 patients in the early pramipexole group and 61 patients in 
the delayed pramipexole group were included in the neuroimaging substudy, for which the adjusted mean 15-month 
change in striatal ¹²³I-FP-CIT binding was –15·1% (SE 2·1) for early and –14·6% (2·0) for delayed pramipexole 
(diﬀ erence –0·5 percentage points, 95% CI –5·4 to 4·4, p=0·84). Overall, 180 (81%) of patients given early pramipexole 
and 179 (84%) patients given delayed pramipexole reported adverse events (most frequently nausea), and 22 (10%) 
patients in the early pramipexole group and 17 (8%) in the delayed pramipexole group had serious events, two of which 
(hallucinations and orthostatic hypotension) were deemed related to study drug. 
Interpretation By clinical and neuroimaging measures, pramipexole showed little evidence diﬀ erentiating 15-month 
usage from usage delayed for 6–9 months. The results do not support the hypothesis that pramipexole has disease-
modifying eﬀ ects. 
Funding Boehringer Ingelheim GmbH.
Introduction
Parkinson’s disease (PD) is a progressive neuro-
degenerative disorder in which loss of dopaminergic 
neurons of the substantia nigra pars compacta 
underlies the major early motor features by which the 
disease is diagnosed clinically. Although several 
therapeutic strategies are available to treat the 
dopamine deﬁ ciency of PD and have been shown to 
improve motor symptoms, no drug has yet been shown 
unequivocally to slow the progression of the loss of 
dopamine cells.1,2 Development of a therapy to slow 
progression of neurodegeneration in PD is a major 
unmet need.
Pramipexole is a dopamine D2/D3 receptor agonist 
with proven eﬃ  cacy in the treatment of PD motor 
symptoms in early and advanced PD.3 In cell culture 
studies4 and studies in rodents5 and primates,6 
pramipexole showed neuroprotective properties that 
seemed to arise partly by a mitochondria-mediated anti-
apoptotic mecha nism. These results were the basis for 
considering that, in addition to its symptomatic action, 
pramipexole might have a disease-modifying eﬀ ect.
The Pramipexole On Underlying Disease (PROUD) 
study was designed to identify whether early, as opposed 
to delayed, initiation of pramipexole resulted in improved 
outcome, as deﬁ ned by uniﬁ ed Parkinson’s disease rating 
scale (UPDRS) total score.7 We undertook a neuroimaging 
substudy to assess the eﬀ ect of the drug on the rate of 
loss of dopamine transporter binding.8 PROUD is the 
second prospectively designed delayed-start trial in PD, 
and to our knowledge the ﬁ rst to combine clinical and 
neuroimaging endpoints. 
Methods
Patients and study design
PROUD is a randomised, double-blind, placebo-con-
trolled, delayed-start trial of pramipexole in patients with 
early PD. The clinical trial design of PROUD has been 
published previously and the reader is referred to the 
report for detailed discussion of the design.7
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We recruited patients at 98 centres in ten countries 
(Austria, Finland, France, Germany, Italy, Japan, Spain, 
Sweden, the UK, and the USA). Patients were 30–79 years 
(extended from 75 years by protocol amendment in 
October 2006, to facilitate enrolment), had idiopathic PD 
characterised by bradykinesia plus at least two further 
PD signs (resting tremor, rigidity, or asymmetry), were at 
modiﬁ ed Hoehn and Yahr9 stage 1 or 2, were diagnosed 
within the preceding 2 years, and were judged unlikely to 
need symptomatic treatment for at least the next 
6 months, preferably 9 months. We excluded potential 
patients if they were currently using PD drugs, had used 
antipsychotic drugs within the preceding 6 months, or 
had any clinically signiﬁ cant abnormalities unrelated to 
PD in physical ﬁ ndings or laboratory values; we also 
excluded patients with medical or psychiatric disorders 
capable of interfering with study participation or the 
interpretation of study data, and those with any history of 
psychosis, dementia, or major or seasonal depression.
The study was conducted in accordance with its protocol, 
with good clinical practice, and with the provisions of the 
Declaration of Helsinki and its amendments. Before 
patients were enrolled, the protocol, the informed-consent 
form, and all protocol amendments were approved by 
local Institutional Review Boards or Independent Ethics 
Committees. The nature and purpose of the study were 
explained to all patients, who provided written informed 
consent before any study procedures.
Randomisation and masking
Patients were randomly assigned (1:1 ratio) by centralised, 
computerised, sponsor-maintained randomisation 
schedule to receive double-blind pramipexole or placebo. 
Study drug (ie, pramipexole tablets or matching 
placebo) was up-titrated over 4 weeks from 0·125 mg 
three times a day to 0·25 mg three times a day, and 
ﬁ nally 0·5 mg three times a day, a ﬁ xed maintenance 
level shown to provide adequate symptomatic beneﬁ t 
and intended to minimise withdrawal due to adverse 
events in those assigned to active drug. 
At 9 months, or as early as 6 months if an investigator 
elected it for a patient expressing inability to tolerate 
PD symptoms, participants were all assigned to the 
pramipexole regimen, including its double-blind up-
titration. For all patients, the month 9 visit (which could 
be conducted as much as 3 months earlier) marked the 
transition from study period 1 (double-blind pramipexole 
vs placebo) to period 2 (double-blind early vs delayed 
pramipexole). Any patient needing additional PD 
treatment discontinued the study. Non-PD treatment 
(including anti-emetics) was permitted for the welfare of 
the patient, on the basis of investigator judgment. 
All patients and investigators were masked to study 
treatment. Pramipexole tablets and matching placebo 
were given in identical blister packaging.  Masking was 
maintained during period 2 for all but two patients 
unmasked for non-emergencies. An independent 
masked rater distinct from the study investigators 
assessed patients at baseline and 15 months, and was 
separate from the masked investigator who assessed 
patients at every visit.
Procedures
Independent raters assessed the 15-month change from 
baseline in total score on the UPDRS (the sum of part I 
[behaviour, mentation, and mood], part II [activities of 
daily living], and part III [motor function]). A study 
investigator assessed the UPDRS at 3 months, 6 months, 
9 months, and 15 months. The independent rates also 
assessed the clinical global impression-global 
improvement (CGI-I) and clinical global impression-
severity of illness (CGI-S) scales10 applied at 15 months. 
Additionally, at 6–9 months (ie, end of period 1) and at 
15 months (end of period 2), patients assessed their 
quality of life on the Parkinson’s disease questionnaire 
(PDQ-39), the EuroQoL ﬁ ve-dimension questionnaire 
(EQ-5D), and the EuroQoL visual analogue scale 
(EQVAS). Patients also completed the Beck depression 
inventory version 1A (BDI). 
The imaging substudy group was a subset of patients 
in the PROUD study who provided additional consent 
for this substudy and who had a baseline and a post-
baseline (15 months) assessment of striatal dopamine 
transporter density, as measured by SPECT at sites with 
tracer availability.8 Striatal binding of ¹²³I-FP-CIT, a 
marker of dopamine-transporter density, was assessed by 
standardised SPECT and interpreted centrally by one of 
the lead investigators (KM).
We assessed safety and tolerability descriptively from 
the incidence, types, and severity of reported adverse 
events and the incidence of withdrawal due to adverse 
events. At months 1, 6, 9, 12, and 15, we assessed the 
incidence of impulse control disorders by the modiﬁ ed 
Minnesota impulsive disorders interview (mMIDI),11 
consisting of items on gambling, compulsive buying, 
and compulsive sexual behaviour.
Statistical analyses 
The primary outcome variable was the 15-month change 
from baseline in total score on the UPDRS, as assessed 
by an independent rater. Secondary assessments 
included the UPDRS assessed  at 3, 6, 9, and 15 months 
by a study investigator and the CGI-I and CGI-S applied 
at 15 months by the independent raters. 
The period 2 full-analysis set included all patients 
randomly assigned to treatment who took at least one 
dose of study drug and had  UPDRS scores assessed by 
an independent rater at baseline and at least once during 
period 2. In this set, we compared mean 15-month 
change in total UPDRS score between patients assigned 
to early pramipexole versus delayed pramipexole using 
analysis of covariance (ANCOVA), with country and 
baseline score as covariates. We expected the ﬁ nal 
UPDRS total score at month 15 to be correlated with the 
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baseline score. Therefore, we selected an ANCOVA 
model for the primary analysis change in UPDRS total 
score from baseline at the end of the second maintenance 
phase (ie, period 2; month 15) with factors treatment and 
centre and the covariate UPDRS total score at baseline. 
For patients who discontinued prematurely during 
period 2, we used scores at their time of withdrawal for 
analysis. 
On the basis of results from a previous trial,12 we did a 
post-hoc analysis of the change in 15-month total score 
separately in patients with baseline total scores of 25 or 
higher and in those with total scores lower than 25. We 
also analysed other UPDRS score changes by ANCOVA 
including the slope of total-score change from month 3 to 
month 9 in all patients with at least two UPDRS 
assessments during period 1. We calculated the slope as 
the diﬀ erence between the last and ﬁ rst UPDRS 
observations during this period divided by the number of 
weeks between these observations. We analysed changes 
in quality of life ratings using Wilcoxon rank sum tests 
with treatment eﬀ ects summarised by Hodges-Lehmann 
estimates. We analysed BDI changes as the sum of 21 item 
scores. We collapsed CGI-I ratings into three categories—
much or very much improved, essentially unchanged, and 
much or very much worse—and analysed these groups 
for odds of category improvement using multinomial 
logistic regression (with terms for treatment, country, and 
CGI-S). On CGI-S, we deﬁ ned changes of one rating point 
or fewer as essentially unchanged. 
In the neuroimaging substudy, we analysed mean 
binding change by ANCOVA (with adjustment for centre 
and baseline value). We imputed missing data using last 
observation carried forward, although we accept that this 
method has limitations.13 
On the basis of previous data for pramipexole in early 
PD clinical trials,14,15 using nQuery Advisor Release 4.0 
(Statistical Solutions), we calculated a sample size of 
190 participants per group to provide 80% power to 
detect a three-point group diﬀ erence in mean 15-month 
change in UPDRS total score, assuming SD 10·4 points 
and a signiﬁ cance level of 5% (two-tailed).7 To compensate 
for the anticipated 24% rate of withdrawal during 
period 1, we increased the sample size to 250 participants 
per group (500 participants in total). This trial is 
registered with ClinicalTrials.gov, number NCT00321854.
Role of the funding source
The sponsor of the study, together with the independent 
lead investigators (independent authors of this report) 
had a role in study design, data collection, data analysis, 
and data interpretation, and also supported the reporting 
of study results, partly as employer of some of the 
authors. AHVS drafted the report. AHVS and all authors 
had full access to all the data and contributed to the 
revision of the report. The corresponding author, AHVS, 
had ﬁ nal responsibility for the decision to submit  for 
publication.
Results
We recruited patients between May 24, 2006, and April 22, 
2009. Of 593 patients screened, 535 were randomly 
assigned to either early pramipexole (261 patients) or 
delayed pramipexole (274 patients; ﬁ gure 1). 221 (85%) of 
261 patients assigned to early pramipexole and 214 (78%) 
of 274 patients assigned to delayed pramipexole 
(ie, placebo) completed period 1 of the study. Of patients 
who entered period 2, 45 (20%) of 221 patients who 
received early pramipexole did so before 9 months, 
compared with 65 (30%) of 214 patients who received 
delayed pramipexole. Of the 435 patients entering 
period 2, 198 (90%) of the patients in the early pramipexole 
group (or 76% of the initial group) and 192 (90%) of the 
patients in the delayed pramipexole group (or 70% of the 
initial group) completed period 2. In both treatment 
groups during both periods, adverse events were the main 
reason for premature discontinuation (ﬁ gure 1). The most 
common adverse events leading to premature 
discontinuation in the delayed group during period 1 were 
related to need for symptomatic PD treatment. Overall, 
mean compliance with treatment (expressed as percentage 
593 patients screened
535 randomised
261 assigned to early pramipexole
40 prematurely discontinued 
period 1
    25 adverse events (including  
         1 with worsened PD)
      4 inadequate eﬃcacy 
      5 non-compliance 
      5 withdrew consent 
      1 other 
221 entered period 2 (including 
45 before 9 months)
23 prematurely discontinued 
period 2
    16 adverse events (including  
          5 with worsened PD)
      5 no eﬃcacy 
      1 non-compliance 
      1 withdrew consent 
221 entered period 2198 completed period 2
274 assigned to delayed pramipexole 
(given placebo in period 1, 
pramipexole in period 2)
60 prematurely discontinued 
period 1
    26 adverse events (including  
          15 with worsened PD)
    12 inadequate eﬃcacy 
      3 non-compliance 
    16 withdrew consent 
      2 lost to follow up
      1 other 
214 entered period 2 (including 
65 before 9 months)
22 prematurely discontinued 
period 2
    17 adverse events (including  
          4 with worsened PD)
      2 no eﬃcacy 
      2 non-compliance 
      1 withdrew consent 
221 entered period 2192 completed period 2
58 ineligible
Figure 1: Trial proﬁ le
PD=Parkinson’s disease. 
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of prescribed doses taken) was 95·9% (SD 10·3) in the 
early pramipexole group and 95·3% (12·5) in the delayed 
pramipexole group.
The groups were similar in terms of demographic and 
clinical characteristics at baseline (table 1). In 195 (75%) 
of 261 patients assigned to early pramipexole and 
199 (73%) of 274 patients assigned to delayed pramipexole, 
PD had been diagnosed 6 months or less before baseline.
For period 1, recipients of early pramipexole showed 
relative stability in total UPDRS scores: in the period 2 
full-analysis set, the adjusted mean change over the ﬁ rst 
6–9 months of the study was –0·5 (SE 0·6) points, as 
assessed by study investigators, compared with 4·3 (0·6) 
for placebo recipients, a diﬀ erence of –4·8 points (95% CI 
–6·3 to –3·2, p<0·0001; table 2). In months 3–9, the 
adjusted mean slope of the total score change in the 
period 1 full-analysis set was 0·11 (SE 0·04) points per 
week in the early pramipexole group, compared with 
0·22 (0·04) for delayed pramipexole group, a diﬀ erence 
of –0·10 (95% CI –0·19 to –0·01, p=0·03). At 9 months, 
all three quality of life scales and the BDI exhibited 
signiﬁ cant diﬀ erences favouring pramipexole (table 3).
In period 2, the adjusted mean change in UPDRS total 
score at 15 months as assessed by independent raters 
(the primary outcome variable), was 0·3 (SE 0·7) points 
in the early pramipexole group and 0·7 (0·7) points in 
the delayed pramipexole group, a diﬀ erence of –0·4 
(95% CI –2·2 to 1·4, p=0·65). At endpoint, the adjusted 
mean total scores were 24·5 (SE 0·7) in the early 
pramipexole group and 24·9 (0·7) in the delayed 
pramipexole group. For ratings by study investigators, 
ﬁ gure 2 shows the 15-month time course of the adjusted 
mean total score change in each treatment group. The 
adjusted mean 15-month change was 0·6 (SE 0·7) points 
in the early pramipexole group and 0·5 (0·7) points in 
the delayed pramipexole group (95% CI –1·7 to 1·8, 
p=0·96). Findings for UPDRS part I, part II, part III, and 
total score are provided in table 2. 
At 15 months, two of the three quality of life measures 
and the mean BDI score did not diﬀ er signiﬁ cantly 
between treatment groups. The third quality of life scale, 
the EQVAS, continued to show a small diﬀ erence that 
favoured early pramipexole but was of doubtful clinical 
signiﬁ cance (table 3). At 15 months, the odds ratio for 
CGI-I category improvement was 0·81 (95% CI 
0·44–1·48, p=0·50), with 176 (88%) of 200 patients in the 
early pramipexole group and 158 (86%) of 184 patients in 
the delayed pramipexole group rated as essentially 
unchanged from baseline. By CGI-S, the odds ratio was 
0·79 (95% CI 0·40–3·30, p=0·79), with 200 (96%) of 
209 patients in the early pramipexole group and 191 (96%) 
of 198 patients in the delayed pramipexole group 
essentially unchanged from baseline.  
Of 160 patients in the neuroimaging substudy, 123 (77%) 
underwent SPECT at both baseline and 15 months. In 
62 patients in the early pramipexole group and 61 patients 
in the delayed pramipexole group, the adjusted mean 
15-month change in striatal ¹²³I-FP-CIT binding was 
–15·1% (SE 2·1) for early and –14·6% (2·0) for delayed 
pramipexole, a diﬀ erence of –0·5 percentage points 
(95% CI –5·4 to 4·4, p=0·84). In 14 (9%) patients recruited 
to the substudy (individuals without evidence of dopamine 
deﬁ ciency), baseline scans were subsequently deemed to 
be normal. Eight of these patients (ﬁ ve in the early 
pramipexole group and three in the delayed pramipexole 
group) underwent a 15-month scan. With their exclusion, 
the adjusted mean change was –15·5% (2·2) for early and 
–14·2% (2·0) for delayed pramipexole, a diﬀ erence of 
–1·3 percentage points (95% CI –6·3 to 3·7, p=0·60).
In the post-hoc analysis of UPDRS outcome by baseline 
score, of the 228 patients with a baseline UPDRS total 
score of less than 25 as assessed by independent raters, 
All patients Period 2 full-analysis set
Early pramipexole 
group (n=261)
Delayed pramipexole 
group (n=274)
Early pramipexole 
group (n=211)
Delayed pramipexole 
group (n=200)
Age (years) 
Mean (SD) 62·1 (10·1) 62·9 (9·9) 62·0 (9·9) 62·2 (10·0)
Median (IQR) 64·0 (56·0–70·0) 64·0 (57·0–70·0) 64·0 (57·0–69·0) 63·0 (55·5–70·0)
Sex
Male 177 (68%) 166 (61%) 146 (69%) 120 (60%)
Female 84 (32%) 108 (39%) 65 (31%) 80 (40%)
Race 
White 251 (96%) 261 (95%) 201 (95%) 189 (94%)
Asian 9 (3%) 10 (4%) 9 (4%) 9 (4%)
Black 1 (<1%) 3 (1%) 1 (<1%) 2 (1%)
PD duration (months)
Mean (SD) 4·4 (6·3) 4·5 (5·9) 4·5 (5·5) 4·8 (6·1)
Median (IQR) 1·8 (0·6–6·1) 1·7 (0·5–6·6) 1·9 (0·7–6·7) 2·0 (0·5–7·1)
Hoehn and Yahr stage 
1·0 93 (36%) 120 (4%) 73 (35%) 88 (44%)
1·5 59 (23%) 50 (18%) 54 (26%) 39 (20%)
2·0 109 (4%) 104 (38%) 84 (40%) 73 (36%)
UPDRS total score
By 
independent 
rater
24·2 (10·5)*; 
23·0 (16·0–31·0)*
25·0 (11·2); 
24·0 (16·0–32·0)
24·2 (10·4); 
23·0 (16·0–30·0)
24·1 (10·3); 
23·0 (16·0–30·0)
By study 
investigator
23·7 (10·0)†; 
22·0 (17·0–29·0)†
24·1 (10·7)‡; 
23·0 (16·0–32·0)‡
23·3 (9·6)§; 
22·0 (17·0–29·0)§
23·3 (10·1); 
21·0 (16·0–30·0)
Quality of life ratings
PDQ-39 total 
score
10·0 (4·7–17·0)† 9·4 (5·1–17·9)‡ 9·8 (4·5–15·5) 9·3 (4·8–16·5)
EQ-5D total 
score
0·78 (0·69–1·00) 0·78 (0·69–1·00)‡ 0·78 (0·69–1·00) 0·78 (0·69–1·00)
EQVAS 80 (70–87) 80 (70–90) 80 (70–88) 80 (70–90)
BDI total score 
Mean (SD) 6·4 (5·5) 6·7 (5·7)‡ 6·1 (5·4) 6·3 (5·6)¶
Median (IQR) 5·0 (2·0–9·0) 5·0 (2·0–10·0)‡ 5·0 (2·0–9·0) 5·0 (2·0–9·0)¶
All data are mean (SD), median (IQR), or number of patients (%). BDI=Beck depression inventory. EQ-5D=EuroQoL 
ﬁ ve-dimension questionnaire. EQVAS=EuroQoL visual analogue scale. PD=Parkinson’s disease. PDQ-39=39-item 
Parkinson’s disease questionnaire. UPDRS total score=Uniﬁ ed Parkinson’s disease rating scale, sum of parts I, II, and III. 
*n=259. †n=260. ‡n=273. §n=210. ¶n=199.
Table 1: Baseline characteristics of patients
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the adjusted mean 15-month change was 1·8 (SE 0·8) 
points in the early and 2·8 (0·8) in the delayed pramipexole 
group, a diﬀ erence of −1·1 (95% CI −3·0 to 0·9, p=0·28). 
Of the 183 patients with a baseline score of 25 or higher, 
the adjusted mean changes were –1·9 (1·4) in the early 
pramipexole group and –2·3 (1·3) in the delayed 
pramipexole group, a diﬀ erence of 0·3 (95% CI 
−2·8 to 3·5, p=0·83).
A post-hoc analysis of all patients entering period 2 of 
the study (N=435) in which we imputed values for 
patients with no post-baseline data and for patients who 
prematurely withdrew from the study (imputed n=55), 
produced a diﬀ erence between treatment groups in total 
UPDRS at 15 months of –0·44 (95% CI –2·25 to 1·37), 
p=0·6302.
During period 1, the frequencies of adverse events, 
serious adverse events, and adverse events leading to 
study-drug discontinuation were similar in the two 
treatment groups (but worsened PD was much more 
frequent as a reason for discontinuation in the placebo 
Early 
pramipexole 
group 
(n=208–211)*
Delayed 
pramipexole 
group 
(n=197–200)*
Diﬀ erence (95% CI)†; 
p value‡
PDQ-39 total score 
9 months –0·5 
(–3·6 to 2·0)
1·4 
(–2·2 to 5·0)
–2·0 (–3·1 to –0·9); 
0·0001
15 months –0·4 
(–3·2 to 3·8)
0·3 
(–3·6 to 4·4)
–0·6 (–1·8 to 0·7); 
0·215
EQ-5D total score 
9 months 0·00 
(–0·03 to 0·09)
0·00 
(–0·14 to 0·00)
0·05 (0·00 to 0·09); 
<0·0001
15 months 0·00 
(–0·03 to 0·09)
0·00 
(–0·08 to 0·08)
0·00 (0·00 to 0·03); 
0·261
EQVAS
9 months 0·0 
(–5·5 to 5·0)
–0·5 
(–10·0 to 5·0)
3·0 (0·0 to 5·0); 0·028
15 months 0·0 
(–8·0 to 7·0)
0·0 
(–10·0 to 2·0)
2·0 (0·0 to 5·0); 0·049
BDI, adjusted† 
9 months –1·1 (0·3) 0·3 (0·3) –1·4 (–2·2 to –0·6); 
0·0009
15 months –1·0 (0·3) –0·5 (0·3) –0·5 (–1·3 to 0·2); 
0·1702
Data are median change (IQR) or mean change (SE), unless otherwise indicated. 
ANCOVA=analysis of covariance. BDI=Beck depression inventory. EQ-5D=EuroQoL 
ﬁ ve-dimension questionnaire. EQVAS=EuroQoL visual analogue scale. PDQ-
39=39-item Parkinson’s disease questionnaire. *Depending on timepoint. †For 
quality of life measures, Hodges-Lehmann estimate. For BDI, adjusted for baseline 
and country. ‡For quality of life measures, Wilcoxon rank sum test, stratiﬁ ed by 
country. For BDI, ANCOVA adjusted for baseline and country. 
Table 3: Changes on quality of life scales and BDI by timepoint (period 2 
full-analysis set) 
Early pramipexole (n=210)*
Delayed pramipexole (n=200)†
7·5
5·0
2·0
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Figure 2: 15-month time course of UPDRS total score (study investigators’ 
ratings; period 2 full-analysis set)
UPDRS total score was the sum of parts I. II, and III; means were adjusted for 
country and baseline. 95% CIs are shown at every timepoint. UPDRS=uniﬁ ed 
Parkinson’s disease rating scale. *n=210 at all timepoints, one patient was 
excluded because of missing baseline data. †n=200 at all timepoints with the 
exception of month 3 (n=198).
Adjusted mean change (SE) Diﬀ erence (95% CI); 
p value†
Early 
pramipexole 
group 
(n=210 or 211)*
Delayed 
pramipexole 
group
(n=200)
UPDRS total score‡
Independent rater
15 months 0·3 (0·7) 0·7 (0·7) –0·4 (–2·2 to 1·4); 0·65
Study investigator
9 months –0·5 (0·6) 4·3 (0·6) –4·8 (–6·3 to –3·2); 
<0·0001
15 months 0·6 (0·7) 0·5 (0·7) 0·0 (–1·7 to 1·8); 0·96
UPDRS part I
Independent rater
15 months –0·3 (0·1) 0·0 (0·1) –0·3 (–0·5 to 0·0); 0·04
Study investigator
9 months –0·2 (0·1) 0·1 (0·1) –0·3 (–0·5 to –0·1); 0·02
15 months –0·2 (0·1) –0·1 (0·1) 0·2 (–0·4 to 0·1); 0·16
UPDRS part II
Independent rater
15 months 0·5 (0·2) 0·4 (0·2) 0·0 (–0·6 to 0·6); 0·93
Study investigator
9 months 0·4 (0·2) 1·5 (0·2) –1·1 (–1·7 to –0·5); 
0·0001
15 months 0·6 (0·2) 0·6 (0·2) 0·0 (–0·6 to 0·6); 0·98
UPDRS part III 
Independent rater
15 months 0·1 (0·5) 0·3 (0·5) –0·2 (–1·5 to 1·1); 0·80
Study investigator
9 months –0·6 (0·5) 2·7 (0·5) –3·3 (–4·5 to –2·2); 
<0·0001
15 months 0·2 (0·5) –0·1 (0·5) 0·2 (–1·1 to 1·5); 0·74
ANCOVA=analysis of covariance. UPDRS=uniﬁ ed Parkinson’s disease rating scale. 
*Depending on timepoint. †ANCOVA adjusted for country and baseline. ‡Total of 
parts I, II, and III.
Table 2: Adjusted mean changes on UPDRS part I, part II, part III, and 
total score (period 2 full-analysis set)
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group than in the pramipexole group; ﬁ gure 1), whereas 
severe adverse events and study-drug-related adverse 
events were more frequent for pramipexole than for 
placebo (table 4). Among serious adverse events with 
onset during period 1, one event (hallucinations 
necessitating the admission to hospital of a patient in the 
early pramipexole group) was judged to be study-drug-
related. For patients who entered period 2, adverse events 
occurring at any time during the 15-month study were 
similar across groups (table 4). Among serious adverse 
events with onset during period 2, one event (orthostatic 
hypotension necessitating the admission to hospital of a 
patient in the delayed pramipexole group) was judged to 
be study-drug related. In both groups, the most frequently 
reported type of adverse event was nausea. Nine patients 
in the early pramipexole group and three in the delayed 
pramipexole group required anti-emetics, and eight 
patients in the early pramipexole group and two in the 
delayed pramipexole group withdrew as a result of nausea 
in period 1, and two from each group in period 2. In the 
early pramipexole group, 35 (13%) of 261 patients 
discontinued because of adverse events not related to 
worsening of PD, including 24 (9%) of 261 patients 
during period 1 and 11 (5%) of 221 patients during 
period 2. In the delayed pramipexole group, the frequency 
was 13 (6%) of 214 patients during period 2 (ie, while 
taking pramipexole).
By mMIDI, compulsive sexual behaviour was identiﬁ ed 
in ﬁ ve patients: two in the early pramipexole group (at 
6 months and subsequently), and three in the delayed 
pramipexole group (one at baseline only, one at 12 months 
only, and one at 12 months and subsequently). 
Compulsive buying was identiﬁ ed in ﬁ ve patients, all in 
the early pramipexole group (one at baseline only, one at 
baseline and subsequently, one at 6 and 9 months only, 
one at 9 months and subsequently, and one at 15 months 
only). Compulsive gambling was not identiﬁ ed at any 
time in any patient.
Discussion
At a maintenance dose of 1·5 mg per day in patients with 
early PD, at 15 months, UPDRS scores, clinical global 
impression ratings, quality of life ratings, and BDI score 
did not diﬀ er signiﬁ cantly between those  given early 
pramipexole and those given delayed pramipexole. 
Additionally, 15-month ¹²³I-FP-CIT neuroimaging 
ﬁ ndings showed a decrease in striatal dopamine-
transporter binding that was equivalent in the early and 
delayed starters. In the ﬁ rst 6–9 months, the clinical 
eﬃ  cacy of pramipexole relative to placebo in improving 
motor function and quality of life was conﬁ rmed at 
a dose limited to 1·5 mg daily, although an increase in 
drug-related adverse events was noted. The diﬀ erence in 
UPDRS in period 1 was a consequence of deterioration 
from baseline in the placebo group; the group receiving 
1·5 mg of pramipexole had returned to baseline. 
The simplest explanation of the PROUD results would 
be that pramipexole does not have any disease-modifying 
action in PD, a conclusion supported by both the clinical 
and the neuroimaging endpoints. However, certain factors 
could potentially confound this interpretation. For 
instance, the symptomatic eﬀ ect of pramipexole might 
have obscured a diﬀ erence between the treatment groups 
at 15 months. This possibility is not supported by the 
Early pramipexole 
group 
Delayed pramipexole 
(placebo) group 
Period 1
Number of patients 
treated during period 1
261 274
Any adverse events 194 (74%) 196 (72%)
Severe adverse events 34 (13%) 23 (8%)
Serious adverse events 17 (7%) 18 (7%)
Study-drug-related 
adverse events
113 (43%) 72 (26%)
Adverse events leading to 
discontinuation
25 (10%) 26 (9%)
Nausea* 54 (21%) 21 (8%)
Dizziness* 29 (11%) 24 (9%)
Somnolence* 28 (11%) 9 (3%)
Fatigue* 26 (10%) 21 (8%)
Headache* 17 (7%) 23 (8%)
Insomnia* 17 (7%) 8 (3%)
Peripheral oedema* 17 (7%) 4 (1%)
Constipation* 16 (6%) 20 (7%)
Nasopharyngitis* 16 (6%) 15 (5%)
Back pain* 14 (5%) 13 (5%)
Depression* 13 (5%) 12 (4%)
Hallucination* 13 (5%) 3 (1%)
Diarrhoea* 8 (3%) 15 (5%)
Periods 1 and 2
Number of patients 
treated during period 2
221 214
Any adverse events 180 (81%) 179 (84%)
Severe adverse events 28 (13%) 24 (11%)
Serious adverse events 22 (10%) 17 (8%)
Study-drug-related
adverse events
102 (46%) 105 (49%)
Adverse events leading to 
discontinuation
16 (7%) 17 (8%)
Nausea† 48 (22%) 45 (21%)
Somnolence† 30 (14%) 19 (9%)
Fatigue† 29 (13%) 34 (16%)
Dizziness† 24 (11%) 28 (13%)
Back pain† 23 (10%) 17 (8%)
Insomnia† 22 (10%) 19 (9%)
Peripheral oedema† 22 (10%) 13 (6%)
Nasopharyngitis† 18 (8%) 24 (11%)
Constipation† 17 (8%) 26 (12%)
MedDRA=Medical Dictionary for Regulatory Aﬀ airs. *Event types (by MedDRA 
preferred term) reported in ≥5% of patients in either group. †Event types (by 
MedDRA preferred term) reported in ≥10% of patients in either group. 
Table 4: Adverse events 
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neuroimaging data, assuming that striatal loss of 
dopamine-transporter binding is an accurate marker of 
PD-related nigrostriatal neurodegeneration and has the 
capacity to detect a meaningful group diﬀ erence in change 
over 15 months. A concern is that patients with slow PD 
progression might have been over-represented among the 
PROUD participants, a consequence of the selection of 
patients deemed likely to tolerate a placebo phase of 
6–9 months. In this case, the PROUD study design might 
be inherently unable to detect a disease-modifying eﬀ ect 
that evolves over a time span exceeding 6–9 months.
The clinical results of the PROUD study can be 
compared with those of the Attenuation of Disease 
Progression with Azilect Given Once-daily (ADAGIO) 
study,12 a delayed-start trial of the monoamine oxidase B 
inhibitor rasagiline administered at 1 mg or 2 mg per 
day in early PD. Generally, the baseline characteristics 
of the patients recruited in these two studies were 
similar, although the mean UPDRS total score was 
20·4 (SD 8·5) in ADAGIO, compared with 24·6 (10·9) 
for independent ratings or 23·9 (10·3) for study 
investigators’ ratings in PROUD. Moreover, both trials 
had a target 36-week initial phase (for active treatment 
vs placebo), although ADAGIO had a second phase 
lasting 36 weeks whereas PROUD had a 24-week second 
phase. In patients who had delayed treatment, the 
annualised rate of progression of UPDRS total score on 
placebo was 6·2 points in ADAGIO, similar to the rate 
of 5·5 points in PROUD.
ADAGIO had three hierarchical endpoints and showed 
that for a dose of 1 mg a day of rasagiline, patients who 
received active drug early maintained a 1·7-point diﬀ erence 
in UPDRS total-score change at week 72 compared with 
those in the delayed-start group. Analyses also suggested 
that the mean responses were not converging to one 
another in these two groups near the end of follow-up. 
Mean response at week 72 did not diﬀ er between early and 
delayed starters at the higher dose of 2 mg per day. A post-
hoc analysis yielded results for both doses consistent with 
a disease-modifying eﬀ ect if the analyses were restricted to 
patients with baseline UPDRS total scores in the highest 
quartile (>25·5 points), although ﬁ ndings for patients in 
the lower three quartiles then failed to attain statistical 
signiﬁ cance. This might imply that a ﬂ oor eﬀ ect for 
UPDRS rating of early PD might have masked a potential 
disease-modifying eﬀ ect of rasagiline at the dose of 2 mg per 
day. In PROUD, however, the results concerning the 
primary outcome variable, 15-month change in UPDRS 
total score, were consistent in subgroups stratiﬁ ed by 
baseline UPDRS scores greater or less than 25.
Both PROUD and ADAGIO showed slope of 
progression for the early treated group in the ﬁ rst phase 
of the study that was slower than, and signiﬁ cantly 
diﬀ erent from, the slope for the untreated group. The 
interpretation of this result is complex. For instance, it 
could simply portray a gradually increasing symptomatic 
eﬀ ect of intervention as PD progresses.
The results of PROUD have implications not only for 
our understanding of the use of pramipexole in early PD 
but also for the design of disease-modiﬁ cation studies in 
patients with PD (including the selection of patient 
populations and study endpoints) and for the reliance on 
preclinical studies and model systems to identify 
candidate neuroprotective drugs. PROUD conﬁ rms the 
clinical eﬃ  cacy of pramipexole in the treatment of 
early PD. The timing of introduction of symptomatic 
therapy following diagnosis of PD remains a matter to be 
determined according to individual patient need. The 
proposal that earlier dopaminergic therapy might be 
associated with long-term beneﬁ ts remains an interesting 
hypothesis,16 and is supported by the results of ADAGIO,12 
the Deprenyl and Tocopherol Antioxidative Therapy of 
Parkinsonism study (DATATOP),17 and the Earlier versus 
Later Levodopa Therapy in PD study (ELLDOPA),18 but 
not those of PROUD (panel).
In reference to future trial design, there are several 
noteworthy observations. First, the proportion of patients 
without evidence of dopamine deﬁ ciency was smaller in 
PROUD than in similar studies such as ELLDOPA18 and 
the Parkinson Research Examination of CEP-1347 Trial 
Panel: Research in context
Systematic review 
Extensive preclinical evidence suggests that dopamine agonists might have 
neuroprotective properties of relevance to Parkinson’s disease (PD). On April 22, 2013, 
we searched in PubMed for reports of clinical trials, without restriction on language or on 
publication date, using the search terms “delayed-start” plus “Parkinson disease” or 
“Parkinson’s disease”. We identiﬁ ed six reports: ﬁ ve concerning the Azilect Given 
Once-daily (ADAGIO)12,19,20 or TVP-1012 in Early Monotherapy for PD Outpatients 
(TEMPO)21,22 studies of the monoamine-oxidase inhibitor rasagiline, and one7 presenting 
the rationale for the present study of pramipexole, a dopamine agonist. The Deprenyl and 
Tocopherol Antioxidative Therapy of Parkinsonism (DATATOP) study17 tested the ability of 
the monoamine-oxidase inhibitor selegiline with or without the antioxidant tocopherol 
to retard PD progression. Dopamine agonists have also been assessed for ability to slow 
the rate of progression of imaging parameters of dopamine metabolism or dopamine 
transporter density, compared with levodopa (Comparison of the Agonist Pramipexole 
versus Levodopa on Motor Complications of PD [CALM-PD]23,24 and Ropinirole as Early 
Therapy versus L-dopa Positron Emission Tomography [REAL-PET]25 studies). All results of 
the published trials have been negative or inconclusive. 
Interpretation 
In a randomised delayed-start design study using 1·5 mg pramipexole during 6–9 or 
15 months, we noted no diﬀ erence in uniﬁ ed Parkinson’s disease rating scale (UPDRS) 
total score between the early and delayed initiation groups. There was also no diﬀ erence 
in dopamine transporter status by SPECT between the two groups at 15 months. These 
results indicate that pramipexole does not demonstrate an ability to slow progression 
of PD, as judged by UPDRS, over th e 15-month period of the trial, and by contrast with 
the results of previous studies, does not indicate that earlier dopaminergic therapy is 
neuroprotective. Future clinical trials for neuroprotective drugs with symptomatic 
beneﬁ t will need to be designed with consideration for potential confounding factors 
(eg, biased PD sample, suboptimum PD stage for delaying neurodegeneration, 
inadequate study duration, masking by symptomatic eﬀ ect, or suboptimum 
neuroimaging markers).
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(PRECEPT),26 perhaps as a consequence of the more 
stringent diagnostic criteria used in PROUD. Second, 
although patients were recruited only if thought capable 
of remaining untreated preferably for 9 months, about 
25% failed to achieve this. The ability of the delayed-start 
design to address the issue of disease modiﬁ cation rests, 
partly, on the ability to minimise patient withdrawal and 
the resulting missing data. Excessive dropout of fast 
progressing patients from the placebo group might be 
expected to lead to a lower (ie, better) mean UPDRS score 
in those remaining and entering period 2. However, in 
PROUD, the two groups entering period 2 remained well 
matched, making this an unlikely explanation for the 
results noted. Nevertheless, future delayed-start studies 
need to ensure high levels of participation in both early 
and delayed stages and minimise dropout. Third, the 
standard UPDRS might not be the best assessment to 
identify changes in early PD, and might be limited by a 
ﬂ oor eﬀ ect.27 
Recent insights into the causes and mechanisms of PD 
have provided several novel potential targets for disease 
modiﬁ cation.28,29 Developing the most appropriate clinical 
trial design will be crucial to their assessment.
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